Transplantation Technologies & Research

Liviano D’Arcangelo G

Publications

• Research Article
  Advagraf vs. Prograf Immunosuppressive Therapy in De Novo Kidney Transplant: A Single Center Experience
  Author(s): Gaetano La Manna, Todeschini P, Capelli I, Cappuccilli M, Cuna V, Battaglino G, Patregnani L, Liviano D’Arcangelo G and Scolari MPGaetano La Manna, Todeschini P, Capelli I, Cappuccilli M, Cuna V, Battaglino G, Patregnani L, Liviano D’Arcangelo G and Scolari MP
  
  Background: Short-term results of renal transplantation have shown a drastic improvement over time mainly due to changes in immunosuppressive therapy. Non-compliance to therapy is one of the causes of graft loss. Tacrolimus is a cornerstone of immunosuppressive therapy: recently became available Tacrolimus once a day formulation (Advagraf) that could improve the compliance of patients to immunosuppressive therapy. Few are published data about its use in clinical practice. We therefore compared the efficacy and pharmacokinetics of once-daily formulation compared to the classic twice-daily dosing tacrolimus in de novo kidney transplant patients. Methods: Retrospectively evaluation of 30 de novo transplant recipients treated with Advagraf in 2009-2012 (on dose daily of 0.2-0.3 mg/kg) and 30 treated with Prograf (2 doses daily of 0.2 mg /kg.. Read More»
  DOI: 10.4172/2161-0991.1000129

  Abstract PDF